Processing

Please wait...

Settings

Settings

1. WO2016062792 - NEW COMPOUNDS AS NIK INHIBITORS

Publication Number WO/2016/062792
Publication Date 28.04.2016
International Application No. PCT/EP2015/074437
International Filing Date 22.10.2015
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C07D 471/04 (2006.01)
A61K 31/505 (2006.01)
A61P 35/00 (2006.01)
CPC
A61K 31/437
A61K 31/506
C07B 2200/05
C07D 471/04
Applicants
  • JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30 B-2340 Beerse, BE
Inventors
  • HYND, George; GB
  • TISSELLI, Patrizia; GB
  • KULAGOWSKI, Janusz, Jozef; GB
  • MACLEOD, Calum; GB
  • MANN, Samuel, Edward; GB
  • PRICE, Stephen, Colin; GB
  • MONTANA, John, Gary; GB
Agents
  • LENAERTS, Philip; BE
Priority Data
14190068.823.10.2014EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NEW COMPOUNDS AS NIK INHIBITORS
(FR) NOUVEAUX COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE NIK
Abstract
(EN)
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-ĸB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
(FR)
Cette invention concerne des agents pharmaceutiques utiles à titre thérapeutique et/ou prophylactique chez un mammifère, et en particulier des inhibiteurs de la kinase induisant le NF-κB (NIK, également connue sous le nom de MAP3K14) utiles pour traiter des maladies telles que le cancer, les troubles inflammatoires, les troubles métaboliques et les troubles auto-immuns. La présente invention concerne également des compositions pharmaceutiques contenant lesdits composés, des procédés de préparation de ces composés et compositions, et l'utilisation de ces composés ou compositions pharmaceutiques pour prévenir ou traiter des maladies telles que le cancer, les troubles inflammatoires, les troubles métaboliques, y compris l'obésité et le diabète, et les troubles auto-immuns.
Latest bibliographic data on file with the International Bureau